4.37
+0.92%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Taysha Gene Therapies
From its filings with the US Securities and Exchange Commission
Taysha Gene Therapies is based in Dallas, Texas and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker TSHA. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $9.8m and a net loss of $109.0m. At that date it held total assets of $343.3m and shareholders' equity of $246.9m.
We are a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. Our lead clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, we aim to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. Our management team has proven experience in gene therapy development and commercialization. We leverage this experience, our manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside.
We are evaluating TSHA-102 for the treatment of females with Rett syndrome in our REVEAL and ASPIRE clinical trials.
The REVEAL Phase 1/2 Adolescent and Adult Trial, also known as Part A, is a first-in-human, open-label, randomized, dose-escalation and dose-expansion study evaluating the safety and preliminary efficacy of TSHA-102 as a single lumbar intrathecal administration in adolescent and adult females aged 12 years and older with Rett syndrome due to MECP2 loss-of-function mutation. The trial is taking place in Canada and the United States. A total of six participants aged 15 to 21 years were treated with TSHA-102 in this study, and enrollment for this trial is complete.
Quoted from its 10-K, filed 19 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 24 Sept 2020
- Employees
- 99
- Website
- tayshagtx.com ↗
- Head office
- 3000 PEGASUS PARK DRIVE, DALLAS, TX, 75247
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Sean NolanChairman of the Board, Chief Executive Officer, since 2020$4.7m
- Dr. Sukumar NagendranPresident, Head of Research and Development, Director, since 2020$3.6m
- Mr. Kamran AlamChief Financial Officer$2.5m
- Mr. Phillip DonenbergIndependent Director$442,361
- Dr. Alison LongIndependent Director$441,444
- Dr. Laura Sepp-LorenzinoIndependent Director$447,361
- Mr. Sean StalfortIndependent Director$437,653
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 41
- Environment
- 39
- Social
- 80
- Governance
- 4
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Taysha Gene Therapies Inc possesses several strengths that give it a competitive edge in the industry. Firstly, the company has a strong pipeline of innovative gene therapies that target a wide range of genetic disorders. This diversified portfolio enables Taysha to address various unmet medical needs, attracting investor interest and potential partnerships.
- Secondly, Taysha has assembled a team of experienced scientists, researchers, and industry professionals who possess deep expertise in gene therapy development. This talented workforce allows the company to accelerate the research and development processes, ensuring efficiency and rapid advancements.
Weaknesses
- Despite its strengths, Taysha Gene Therapies Inc also faces certain weaknesses that need to be addressed. One notable weakness is its heavy reliance on a limited number of gene therapy candidates in its pipeline. This exposes the company to potential setbacks if any of these candidates fail in clinical trials or encounter regulatory hurdles.
- Furthermore, Taysha may face challenges in scaling up production and ensuring affordability of its gene therapies. Manufacturing complex gene therapies at a large scale while keeping treatment costs accessible for patients can be a significant hurdle for the company.
Opportunities
- The gene therapy industry is rapidly evolving, creating promising opportunities for Taysha Gene Therapies Inc. The increasing prevalence of genetic disorders and the growing understanding of genetic drivers provide a robust market for the company's targeted therapies. Taysha can seize the opportunity to make a substantial impact on patient outcomes by addressing these unmet medical needs.
- Additionally, strategic partnerships with academic institutions, research organizations, and biotech companies can facilitate knowledge exchange, access to novel technologies, and potential collaborations. These partnerships can enhance Taysha's research capabilities, expand its product pipeline, and drive future growth.
Threats
- Like any other company in the biopharmaceutical industry, Taysha Gene Therapies Inc faces certain threats that must be considered. The competitive landscape is intense, with established players and emerging biotech firms vying for market share. Maintaining a competitive advantage while navigating intellectual property challenges, pricing pressures, and market competition can pose a threat to Taysha's success.
- Moreover, regulatory uncertainties and evolving healthcare policies can impact the development, approval, and commercialization of gene therapies. Changes in reimbursement policies or regulatory standards may lead to delays, increased costs, or market access barriers for Taysha's products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.